Varifarma signed an exclusive distribution and licensing agreement for Ledaga® in Argentina with Recordati AG, Rare Diseases branch, a pharmaceutical company committed to providing often overlooked orphan therapies to the underserved rare disease communities in the World.
Ledaga® (chlormethine hydrochloride) is a novel gel formulation, applied once a day, indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), a rare disease characterized by the abnormal accumulation of malignant T-cells in the skin. MF-CTCL is the most common type of cutaneous lymphoma and first presents as patches and plaques on the skin. It is difficult to diagnose, particularly in the early stages as many of its features are non-specific. Chlormethine is an alkylating agent that inhibits quickly proliferating cells and Ledaga® is recognized to have a good efficacy profile with a confirmed treatment response achieved in 76.7% of the efficacy evaluable population in the pivotal trial (Lessin S.R. et al JAMA Dermatol. 2013; 149(1): 25-32).
Marcelo Conti, Laboratorio Varifarma Director, commented: “It is with great pride and responsibility that we take the license of an innovative product like Ledaga®, from Recordati, in South America. We are anxious to work with a company that shares our principles and work ethic as it aims for great results with a patient-centered approach”
Download Press Release here